Brand-name drug prices skyrocket
Prices for generics, however, are falling. Consumers who have the choice are crazy not to go for generic drugs.
Every time I hear about rising drug prices, I think about how lucky I am that my medications are low-priced generics. Many others are not as fortunate.A study released by Express Scripts found that prices for brand-name drugs rose 13.2% this year, more than six times the rate of inflation. Conversely, prices for generics went down by about 22% during that same time (from September 2011 to September 2012). The pharmaceutical industry, not surprisingly, is disputing the study's findings, saying it was skewed because it included expensive specialty medicines. A spokesperson for the Pharmaceutical Research and Manufacturers of America couldn't immediately be reached.
Express Scripts' report, though, should be a wakeup call even to the healthy, who wind up paying the costs of these drugs either through their health insurance premiums or tax dollars for entitlement programs.
"What it all points to is this: Patients choosing a market basket of brand-name medications instead of clinically equivalent generics are being charged a higher premium than ever before," according to the pharmacy benefits manager. "The financial incentive for both patients and their plan sponsors to switch to generics has never been greater."
Some people are forced to decide between paying their mortgage and their medicine. A study published in 2009 found that medical bills are a factor in more than 60% of personal bankruptcies. Overall health care expenditures hit more than $2 trillion in 2010, more than 10 times the $256 billion spent in 1980, according to the Kaiser Family Foundation. Rising drug costs are one of the main culprits behind all of these problems.
People who have multiple sclerosis know this issue all too well. Some medications to treat the neurological disorder can cost $30,000 a year. A study published in the journal Neurology found that these medications were very expensive and marginally beneficial, according to the New York Times. MS patients try to stretch their health care dollars by skipping doses and splitting pills.
"They have to give up vacations and certain kinds of family events because they just don't have the disposable income," said Dr. Nicholas LaRocca, vice president of health care delivery and policy at the National Multiple Sclerosis Society, in an interview.
The Express Scripts study also found that spending on specialty medicines has increased nearly 23% this year while spending on traditional medicines declined, which illustrates how competition can help keep prices down for everyone. Specialty medicines are also quite lucrative. As the New York Times noted, all but one of the new drugs approved in third quarter were specialty medicines, many of which were approved to treat advanced cancers that other treatments had failed to address.
I am fortunate that the cost to treat my condition averages about $15 every other month and is being managed effectively. Maybe one day, a big pharmaceutical company will develop an expensive blockbuster treatment, but I will cross that bridge when that happens. Maybe like millions of other Americans, I will buy my medications from low-cost Canadian pharmacies.
--Follow Jonathan Berr on Twitter @jdberr. Adds details on MS
More from Money Now
| Tags: | Economy |
I am a physician. The healthcare system in the USA is the most expensive in the world. While it is good, it is far from the best in the world. Why? For profit health insurance and procedure based physician reimbursement. It is not that complicated.
Healthcare that is focused on maintaining health rather than treating end stage disease is not a priority. Those without insurance put off care until it is expensive and this ends up on the public dole. This is an expensive tragedy.
Pharma invests billions in new drugs and the American health consumer largely pays for it while the world benefits. A SINGLE patient in a clinical drug trial I have been involved with cost the study in excess of $25,000. It is very costly. Republicans and their special interest groups largely represent Pharma. It is BIG money. I personally paid less than two Euros in Europe for the exact same medicine from the same manufacturer that costs $38 dollars in the USA.
Healthcare issues in this country are very complex and in need of reform. Don't blame Democrats or Republicans for the cost of pills - it just doesn't make sense and stinks of ignorance.
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
RECENT POSTS
Tired of constantly dying batteries, she came up with a device that could revolutionize energy storage -- and won $50,000 from Intel.
- Detroit in hot water over proposal to sell art
- Sears spirals toward oblivion
- Why aren't heads rolling at the IRS?
- Do we pay attention to roads and bridges now?
- Yahoo may be going after Hulu
- Apple's first computer could fetch $450,000
- AT&T adds sneaky fee onto its wireless bills
- Soaring ER use adds more pain to health costs
- Netflix gets 'Arrested Development' stars cheap
MARKET UPDATE
[BRIEFING.COM] Stocks entered the weekend on a mixed note as the S&P 500 shed 0.1% while the Dow ended with a gain of 0.1%.
The major averages began the day on a lower note as nine of ten sectors saw losses of more than 0.5%.
The consumer staples sector was the lone exception as the group spent the entire day in positive territory thanks to the relative strength of Dow component Procter & Gamble (PG 81.89, +3.19). The second-largest staple stock advanced ... More
More Market News
TOP STOCKS
Try as the bears might, they couldn't break US stocks. But investors still face frothy prices and considerable headwinds.
MSN MONEY'S
- Shared
- Commented
- Viewed



